logo
logo

Hikma Ventures Invests In Tact.Ai, An Ai-Powered Customer Engagement Platform For Life Sciences Companies

Mar 29, 2022•over 3 years ago
London

Description

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has invested in Tact.ai, the customer engagement company for life sciences. Tact.ai helps pharmaceutical companies work more effectively with health care professionals (HCPs) to deliver innovative medicines to patients faster. The investment is the fourth Life Sciences industry investment in the past six months for Tact.ai, following its $33 million USD fundraise last year.

Company Information

Company

Tact.Ai

Location

London, Ontario, Canada

About

Tact.ai is on a mission to help life science organizations nurture meaningful customer engagement through our human-friendly software. Their AI-powered engagement platform empowers field teams to work with their customers in new ways to drive better outcomes. Tact.ai is headquartered in Silicon Valley and is backed by some of the world's leading firms in venture capital, technology, and healthcare and life sciences, including Microsoft's venture fund M12, Salesforce Ventures, Novartis, Lilly and McKesson Ventures. For more information, please visit https://www.tact.ai/ SOURCE Hikma Pharmaceuticals USA Inc.